Catalent to sell New Jersey facility
14/10/2024 11:04
Oct 14 (Reuters) - Catalent CTLT.N said on Monday it had agreed to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena. (Reporting by Bhanvi Satija in Bengaluru; Editing by Anil D'Silva) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled